Back to results
US 5,674,729 AGranted
De novo cell-free synthesis of picornavirus
AssigneeThe Research Foundation of State University of New York
InventorsEckard Wimmer, Akhteruzzaman Molla, Aniko V. Paul
Life of this patent
Estimating the term…
Abstract
A process for the de novo synthesis of a picornavirus using a cell-free medium has been developed. The cell-free medium is prepared from a lysate of mammalian cells from which the nuclei and mitochondria has been removed, endogenous mRNA deactivated and supplemented with nucleoside triphosphates, tRNA, amino acids and precursors necessary for generating proteins. The genomic RNA of the picornavirus or rhinovirus is added to the cell-free medium and after incubation at about 30.degree. C. to 40.degree. C. of from about 4 to 24 hours infectious, mature virus particles are formed.
Claims18
A process for the de novo, in vitro synthesis of picornaviruses comprising:
- A. Preparing a lysate from transformed or tumorigenic mammalian cells selected from the group consisting of kidney cells, epithelial cells, liver cells, cells of the central nervous system, and fibroblastic cells, by removing nuclei and mitochondria from the cells to form an extract, and then deactivating mRNA endogenous to the cells in the extract with micrococcal nuclease, calcium chloride and EGTA;
- B. Preparing an in vitro synthesis medium by mixing:
- (i) said lysate,
- (ii) about 1 mM ATP,
- (iii) about 20 .mu.M to 1000 .mu.M each of GTP, CTP and UTP, or 50 .mu.M of GTP,
- (iv) about 10 mM creatine phosphate,
- (v) about 24 .mu.g/ml creatine phosphokinase,
- (vi) about 2 mM dithiothreitol,
- (vii) about 24 .mu.g/ml calf liver t-RNA,
- (viii) about 12 .mu.M each of 20 amino acids,
- (ix) about 18 mM Hepes, pH 7.4,
- (x) about 240 .mu.M spermidine,
- (xi) about 50 mM to 200 mM potassium acetate, and
- (xii) from about 0.75 mM to 4 mM Mg.sup.++,
- wherein the amounts specified represent the final concentration in the medium;
- C. Adding picornavirus RNA or in vitro synthesized RNA from picornavirus cDNA to the in vitro synthesis medium;
- and
- D. Incubating the in vitro synthesis medium resulting from step C for from about 4 to 24 hours at a temperature of from about 30.degree. C. to 40.degree. C. to produce a mixture of fully assembled virions in the presence of the in vitro synthesis medium, viral RNA, synthesized viral protein and partially assembled virious.
15 more elements
A process for the de novo, in vitro synthesis of polioviruses comprising:
- A. Preparing a lysate from transformed or tumorigenic mammalian cells selected from the group consisting of kidney cells, epithelial cells, liver cells, cells of the central nervous system, and fibroblastic cells, by removing nuclei and mitochondria from the cells to form an extract, and then deactivating mRNA endogenous to the cells in the extract with micrococcal nuclease, calcium chloride and EGTA;
- B. Preparing an in vitro synthesis medium by mixing:
- (i) said lysate,
- (ii) about 1 mM ATP,
- (iii) about 20 .mu.M to 1000 .mu.M each of GTP, CTP and UTP, or 50 .mu.M of GTP,
- (iv) about 10 mM creatine phosphate,
- (v) about 24 .mu.g/ml creatine phosphokinase,
- (vi) about 2 mM dithiothreitol,
- (vii) about 24 .mu.g/ml calf liver t-RNA,
- (viii) about 12 .mu.M each of 20 amino acids,
- (ix) about 18 mM Hepes, pH 7.4,
- (x) about 240 .mu.M spermidine,
- (xi) about 50 mM to 200 mM potassium acetate, and
- (xii) about 0.75 mM to 4 mM Mg.sup.++,
- wherein the amounts specified represent the final concentration in the medium;
- C. Adding poliovirus RNA or in vitro synthesized RNA from poliovirus cDNA to the in vitro synthesis medium;
- and
- D. Incubating the in vitro synthesis medium resulting from step C for about 4 to 24 hours at a temperature of from about 30.degree. C. to 40.degree. C. to produce a mixture of fully assembled virions in the presence of the in vitro synthesis medium, viral RNA, synthesized viral protein and partially assembled virions.
15 more elements
A process for the de novo, in vitro synthesis of rhinoviruses comprising:
- A. Preparing a lysate from transformed or tumorigenic mammalian cells selected from the group consisting of kidney cells, epithelial cells, liver cells, cells of the central nervous system, and fibroblastic cells, by removing nuclei and mitochondria from the cells to form an extract, and then deactivating mRNA endogenous to the cells in the extract with micrococcal nuclease, calcium chloride and EGTA;
- B. Preparing an in vitro synthesis medium by mixing:
- (i) said lysate,
- (ii) about 1 mMATP,
- (iii) about 20 .mu.M to 1000 .mu.M each of GTP,
- CTP and UTP, or 50 .mu.M of GTP,
- (iv) about 10 mM creatine phosphate,
- (v) about 24 .mu.g/ml creatine phosphokinase,
- (vi) about 2 mM dithiothreitol,
- (vii) about 24 .mu.g/ml calf liver t-RNA,
- (viii) about 12 .mu.M each of 20 amino acids,
- (ix) about 18 mM Hepes, pH 7.4,
- (x) about 240 .mu.M spermidine,
- (xi) about 50 mM to 200 mM potassium acetate, and
- (xii) about 0.75 mM to 4 mM Mg.sup.++,
- wherein the amounts specified represent the final concentration in the medium;
- C. Adding rhinovirus RNA or in vitro synthesized RNA from rhinovirus cDNA to the in vitro synthesis medium;
- and
- D. Incubating the in vitro synthesis medium resulting from step C for about 4 to 24 hours at a temperature of about 30.degree. C. to 40.degree. C. to produce a mixture of fully assembled virions in the presence of the in vitro synthesis medium, viral RNA, synthesized viral protein and partially assembled virions.
16 more elements
Dependencies are inferred from the claim text.